A5028771923- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Breast Cancer Treatment Studies
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- T-cell and B-cell Immunology
- Angiogenesis and VEGF in Cancer
- Protein Degradation and Inhibitors
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
Kepler Universitätsklinikum
2019-2025
Ordensklinikum Linz Barmherzige Schwestern
2014-2024
Krankenhaus der Elisabethinen
2018-2024
AGO Austria
2015-2024
Austrian Breast & Colorectal Cancer Study Group
2022-2023
Johannes Kepler University of Linz
2019-2023
Faculty (United Kingdom)
2022
First Congregational Church
2021
Innsbruck Medical University
2000-2019
Medical University of Vienna
2005-2019
Human hematopoiesis originates in a population of stem cells with transplantable lympho-myeloid reconstituting potential, but method for quantitating such has not been available. We now describe simple assay that meets this need. It is based on the ability sublethally irradiated immunodeficient nonobese diabetic– scid/scid (NOD/SCID) mice to be engrafted by intravenously injected human hematopoietic and uses limiting dilution analysis measure frequency produce both CD34 − CD19 + (B-lymphoid)...
A major goal of experimental and clinical hematology is the identification mechanisms conditions that support expansion transplantable hematopoietic stem cells. In normal marrow, such cells appear to be identical (or represent a subset of) population referred as long-term-culture-initiating (LTC-ICs) so-named because their ability produce colony-forming cell (CFC) progeny for > or = 5 weeks when cocultured with stromal fibroblasts. Some LTC-ICs in vitro has recently been described, but...
Abstract Background About 50% of all primary breast cancers show a low-level expression HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack gene amplification measured by in situ hybridization. This low is promising new target for antibody–drug conjugates (ADCs) currently under investigation. Until now, little known about the frequency prognostic value HER2-expression metastatic cancer (MBC). Patients methods The MBC-Registry Austrian Study Group Medical Tumor Therapy (AGMT)...
Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the third- or later-line setting. The primary analysis (median follow-up, 17 months) of phase 2 ELARA trial reported high response rates and excellent safety profile patients extensively pretreated r/r FL. Here, we report longer-term efficacy, safety, pharmacokinetic, exploratory biomarker analyses after median follow-up 29 months (interquartile range, 22.2-37.7). As March 2022, 97 FL (grades...
A high proportion of the CD34+CD38- cells in normal human marrow are defined as long-term culture-initiating (LTC-IC) because they can proliferate and differentiate when co-cultured with cytokine-producing stromal feeder layers. In contrast, very few will divide cytokine-containing methylcellulose thus not classifiable direct colony-forming (CFC), although most serum-free liquid cultures containing certain soluble cytokines. Analysis effects 16 cytokines on latter type culture showed that...
Previous studies have shown that primitive human hematopoietic cells detectable as long-term culture-initiating (LTC-ICs) and colony-forming (CFCs) can be amplified when CD34 + CD38 − marrow are cultured for 10 days in serum-free medium containing flt3 ligand (FL), Steel factor (SF), interleukin (IL)-3, IL-6, granulocyte colony-stimulating factor. We now show the generation of these two cell types such cultures is differentially affected at single level by changes concentrations cytokines....
Purpose To assess the impact of allogeneic hematopoietic stem-cell transplantation (HSCT) from matched related donors (MRDs) and unrelated (MUDs) on outcome in high-risk patients with acute myeloid leukemia (AML) within a prospective multicenter treatment trial. Patients Methods Between 1998 2004, 844 (median age, 48 years; range, 16 to 62 years) AML were enrolled onto protocol AMLHD98A that included risk-adapted strategy. High risk was defined by presence unfavorable cytogenetics and/or no...
Characterization of novel fusion genes in acute leukemia is important for gaining information about genesis. We describe the characterization a new ETV6 gene myeloid (AML) FAB M0 as result an uncommon translocation involving chromosomes 12 and 15.The locus at 12p13 was shown to be translocated constitute 5' end product by break apart fluorescence situ hybridisation (FISH). To identify partner 3' rapid amplification cDNA-ends with polymerase chain reaction (RACE PCR) performed followed...
Abstract Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) myeloid leukemia (CML) and Ph+ CP, accelerated (AP), or blast (BP) CML after prior treatment with tyrosine kinase inhibitors (TKIs). In the ongoing 4 BYOND study (NCT02228382), 163 patients resistant/intolerant to TKIs ( n = 156 CP CML, AP 3 Ph-negative/ BCR-ABL1 + CML) received bosutinib 500 mg once daily (starting dose). As of ≥1 year last enrolled patient (median duration 23.7...
Sensitive screening for Aspergillus spp. using polymerase chain reaction (PCR) of whole blood samples in patients with haematological disorders has not been performed to date. In a 2-year study, 121 admitted the University Hospital Innsbruck cancer chemotherapy without clinical signs fungal infection were prospectively screened 28 out (23%) patients, DNAaemia was detected. Of these 16 (57%) positive only once DNA, but positivity never associated invasive aspergillosis. PCR episodes short and...
Summary. We report a 53‐year‐old man with lymphoid blast crisis of Ph + chronic myeloid leukaemia who was treated STI571, selective inhibitor the enzymatic activity BCR–ABL. He responded excellently to STI571 (600 mg/d), obtaining complete cytogenetic remission after 3 months therapy. Although in bone marrow sustained, patient developed an isolated central nervous system relapse. Subsequent analyses concentrations cerebrospinal fluid (CSF) revealed 2‐log lower CSF levels than corresponding...
We investigated in detail the previously described capacity of pseudohyphae Candida albicans to bind C3-coated particles. show that expression C3bi receptor C. was dependent upon growth temperature fungi. grown at 30 degrees C bound strongly EAC1423bi, whereas those cells 38.5 were completely devoid this capacity. The molecule responsible for attachment EAC1423bi heat labile and trypsin sensitive. Several, but not all, monoclonal antibodies alpha-chain human complement type 3 (CR3) stained...
To define the role of quantitative graft composition and donor killer-cell immunoglobulin-like receptor (KIR) genotype in clinical outcome following unmanipulated peripheral blood stem cell transplantation (PBSCT) from human leucocyte antigen (HLA)-identical siblings, 43 consecutive transplants for haematological malignancies were analysed retrospectively. Twenty-four patients underwent myeloablative conditioning 19 received busulphan/fludarabine-based reduced intensity (RIC). In with acute...
Neoadjuvant chemotherapy (NaCT) and neoadjuvant endocrine therapy (NET) can reduce pre-operative tumour burden in patients with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative early-stage breast cancer. This prospective translational study assessed the ability of a 12-gene molecular score (MS; EndoPredict®) to predict response NaCT or NET within ABCSG-34 trial.Hormone (HR)-positive, HER2-negative samples from randomized phase II trial were selected...
The pretreatment De Ritis ratio [aspartate transaminase (AST)/alanine (ALT)] has been shown to be an adverse prognostic marker in various cancer entities. However, its relevance advanced pancreatic ductal adenocarcinoma (PDAC) not yet studied. In the present study we investigated AST/ALT as a possible predictor of treatment response and disease outcome patients with PDAC treated first-line gemcitabine/nab-paclitaxel.A post hoc analysis prospective, multicenter, noninterventional was...